Sara Cacciapuoti
Overview
Explore the profile of Sara Cacciapuoti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nardone O, Calabrese G, La Mantia A, Villani G, Megna M, Cacciapuoti S, et al.
Therap Adv Gastroenterol
. 2025 Mar;
18:17562848251323529.
PMID: 40041240
Background: Managing extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD) patients remains challenging due to considerable heterogeneity in diagnostic criteria and the lack of a standardised definition and validated diagnostic...
2.
Campanati A, Esposito M, Caldarola G, Cacciapuoti S, Fabbrocini G
Drugs Context
. 2024 Oct;
13.
PMID: 39416771
A fixed-dose combination of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam (Enstilar, LEO Pharma) is the only topical therapy approved for the acute (reactive) and proactive management of psoriasis. Although...
3.
Cacciapuoti S, Battista T, Potestio L, Scalvenzi M, Megna M, Ruggiero A
Clin Exp Dermatol
. 2024 Oct;
50(3):544-550.
PMID: 39400048
Background: Psoriasis may significantly affect the health-related quality of life (HRQoL) of patients. Clinical assessment has been combined with HRQoL scores to evaluate the ways in which cutaneous disease affects...
4.
Bernardini N, Skroza N, Atzori L, Mugheddu C, Megna M, Cacciapuoti S, et al.
Drugs Context
. 2024 Sep;
13.
PMID: 39263599
Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more...
5.
DAgostino M, Feo F, Martora F, Genco L, Megna M, Cacciapuoti S, et al.
Ital J Dermatol Venerol
. 2024 Jul;
159(5):566-571.
PMID: 39039954
Since the development of the artificial intelligence (AI), several applications have been proposed. Among these, the intersection of AI and medicine has sparked a wave of innovation, revolutionizing various aspects...
6.
Cacciapuoti S, Potestio L, Gallo L, Musumeci M, Caldarola G, DAmico D, et al.
Int J Dermatol
. 2024 Jul;
64(2):319-324.
PMID: 38997809
Background: Novel biologics targeting the IL23/T-17 axis, such as tildrakizumab, have been developed to treat psoriasis. There is limited evidence on the use of tildrakizumab for the treatment of psoriasis...
7.
Megna M, DE Lucia M, Fornaro L, Tommasino N, Castiglione F, Cacciapuoti S, et al.
JAAD Case Rep
. 2024 May;
48:11-13.
PMID: 38745828
No abstract available.
8.
Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, et al.
Clin Cosmet Investig Dermatol
. 2024 May;
17:1037-1042.
PMID: 38737943
Tildrakizumab is a humanised IgG1/k-type monoclonal antibody that targets the p19 protein subunit of IL23. Despite its effectiveness and safety have been widely reported by clinical trials and real-life experiences,...
9.
Megna M, Balato A, Caccavale S, Cacciapuoti S, Calabrese G, Di Brizzi E, et al.
J Clin Med
. 2024 May;
13(9).
PMID: 38731081
Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting the p19 subunit of IL23. Its effectiveness and safety were widely reported by clinical trials. However, these results must...
10.
Potestio L, Megna M, Cacciapuoti S, Martora F, Villani A
Clin Exp Dermatol
. 2024 May;
49(11):1427.
PMID: 38717745
No abstract available.